US 12,460,017 B2
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
Leila Marie Boustany, Redwood City, CA (US); Sherry L. La Porte, San Francisco, CA (US); Bryan A. Irving, Woodside, CA (US); and Jeanne Grace Flandez, Oakland, CA (US)
Assigned to CytomX Therapeutics, Inc., South San Francisco, CA (US)
Filed by CytomX Therapeutics, Inc., South San Francisco, CA (US)
Filed on Nov. 13, 2023, as Appl. No. 18/507,167.
Application 18/507,167 is a division of application No. 17/930,143, filed on Sep. 7, 2022, granted, now 11,859,010, issued on Jan. 2, 2024.
Application 17/930,143 is a division of application No. 16/159,451, filed on Oct. 12, 2018, granted, now 11,472,889, issued on Oct. 18, 2022.
Claims priority of provisional application 62/731,622, filed on Sep. 14, 2018.
Claims priority of provisional application 62/666,065, filed on May 2, 2018.
Claims priority of provisional application 62/613,358, filed on Jan. 3, 2018.
Claims priority of provisional application 62/577,140, filed on Oct. 25, 2017.
Claims priority of provisional application 62/572,468, filed on Oct. 14, 2017.
Prior Publication US 2024/0150492 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 31/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C12N 15/62 (2006.01); G01N 33/53 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/40 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C12N 15/62 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01)] 12 Claims
 
1. A purified polypeptide comprising the amino acid sequence of SEQ ID NO: 12.